Citation Impact
Citing Papers
Transcriptomic Signatures Predict Regulators of Drug Synergy and Clinical Regimen Efficacy against Tuberculosis
2019
Crippling life support for SARS-CoV-2 and other viruses through synthetic lethality
2020 StandoutNobel
The protonmotive force is required for maintaining ATP homeostasis and viability of hypoxic, nonreplicating Mycobacterium tuberculosis
2008
A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis
2004 StandoutScience
Compliance of patients and physicians: experience and lessons from tuberculosis-II.
1983
Function and Structure of a Prokaryotic Formylglycine-generating Enzyme
2008 StandoutNobel
PapA3 Is an Acyltransferase Required for Polyacyltrehalose Biosynthesis in Mycobacterium tuberculosis
2009 StandoutNobel
No health without mental health
2007 Standout
Chemotherapy of Pulmonary Tuberculosis
1959
Liver macrophages in murine listeriosis. Cell-mediated immunity is correlated with an influx of macrophages capable of generating reactive oxygen intermediates.
1985 StandoutNobel
Network analysis identifies Rv0324 and Rv0880 as regulators of bedaquiline tolerance in Mycobacterium tuberculosis
2016
Host Cell Autophagy Activated by Antibiotics Is Required for Their Effective Antimycobacterial Drug Action
2012
Mycobacterial protein antigens: a compilation
1992
A view on drug resistance in cancer
2019 StandoutNature
Disruption of response regulator gene,devR, leads to attenuation in virulence ofMycobacterium tuberculosis
2004
The catalase—peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis
1992 Nature
Microbial phenotypic heterogeneity and antibiotic tolerance
2007
Mycobacterial sulfolipid shows a virulence by inhibiting cord factor induced granuloma formation and TNF-α release
2006
Bacterial stress responses as determinants of antimicrobial resistance
2012
The spectrum of latent tuberculosis: rethinking the biology and intervention strategies
2009 Standout
Rapid resolution of tuberculous pericardial effusions with high dose prednisone and anti-tuberculous drugs
1994
Interventions for treating tuberculous pericarditis
2002
The Detection of Airborne Transmission of Tuberculosis from HIV-Infected Patients, Using an In Vivo Air Sampling Model
2007
Elucidation and Chemical Modulation of Sulfolipid-1 Biosynthesis in Mycobacterium tuberculosis
2011 StandoutNobel
The Enduring Hypoxic Response of Mycobacterium tuberculosis
2008
Repurposing clinically approved cephalosporins for tuberculosis therapy
2016
Tuberculosis in Patients with Human Immunodeficiency Virus Infection
1999 Standout
Programmes and principles in treatment of multidrug-resistant tuberculosis
2004
Global Trends in Resistance to Antituberculosis Drugs
2001
The Use of Adenosine Deaminase and Interferon-γ as Diagnostic Tools for Tuberculous Pericarditis
2002
Trehalose Is Required for Growth of Mycobacterium smegmatis
2004 StandoutNobel
Cytological and Transcript Analyses Reveal Fat and Lazy Persister-Like Bacilli in Tuberculous Sputum
2008
Does M. tuberculosis genomic diversity explain disease diversity?
2010
Cell‐Wall Alterations as an Attribute ofMycobacterium tuberculosisin Latent Infection
2003
Global phylogeography of Mycobacterium tuberculosis and implications for tuberculosis product development
2007
5′-Adenosinephosphosulfate Lies at a Metabolic Branch Point in Mycobacteria
2002 StandoutNobel
Bactericidal activity of OPC-67683 against drug-tolerant Mycobacterium tuberculosis
2007
Chemotherapy and management of tuberculosis in the United Kingdom: recommendations 1998
1998
The future challenges facing the development of new antimicrobial drugs
2002
Autophagy in Human Health and Disease
2013 Standout
A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
2010 Standout
Mycobacterial survival strategies in the phagosome: defence against host stresses
2009
Adjuvant corticosteroids for tuberculous pericarditis: promising, but not proven
2003
M. tuberculosis persistence, latency, and drug tolerance
2003
Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis
1993 Standout
The challenge of emerging and re-emerging infectious diseases
2004 StandoutNature
Stationary phase gene expression of Mycobacterium tuberculosis following a progressive nutrient depletion: a model for persistent organisms?
2004
Quantitative Bacillary Response to Treatment in HIV-associated Pulmonary Tuberculosis
1993
Simple Procedure for Drug Susceptibility Testing of Mycobacterium tuberculosis Using a Commercial Colorimetic Assay
1999
Aerodynamic analysis of SARS-CoV-2 in two Wuhan hospitals
2020 StandoutNature
Sarcoidosis
1997 Standout
Emerging carbapenemases in Gram-negative aerobes
2002
Advances in the development of new tuberculosis drugs and treatment regimens
2013
USPHS Tuberculosis Short-Course Chemotherapy Trial 21: Effectiveness, Toxicity, and Acceptability
1990
New use of BCG for recombinant vaccines
1991 StandoutNature
The global situation of MDR-TB
2003
Rapid Molecular Detection of Tuberculosis and Rifampin Resistance
2010 Standout
Chemistry of Class 1 CRISPR-Cas effectors: Binding, editing, and regulation
2020 StandoutNobel
A Novel Pathogenic Taxon of the Mycobacterium tuberculosis Complex, Canetti: Characterization of an Exceptional Isolate from Africa
1997
Drug Targets in Mycobacterial Sulfur Metabolism
2007
Treatment of Multidrug-Resistant Tuberculosis
1993
A pilot study of antituberculosis combinations comparing rifabutin with rifampicin in the treatment of HIV-1 associated tuberculosis
1995
Metabolic Regulation of Mycobacterial Growth and Antibiotic Sensitivity
2011
Molecular Fingerprinting ofMycobacterium tuberculosis: How Can It Help the Clinician?
1997
Molecular detection, identification and drug resistance detection inMycobacterium tuberculosis: Table 1
2009
Evidence for Health Decision Making — Beyond Randomized, Controlled Trials
2017
Corticosteroids and tuberculosis: risks and use as adjunct therapy
1993
Rapid detection of rifampicin resistance in sputum and biopsy specimens from tuberculosis patients by PCR and line probe assay
1995
Comparison of polymerase chain reaction with adenosine deaminase activity in pericardial fluid for the diagnosis of tuberculous pericarditis
2002
Antibacterial drug discovery in the resistance era
2016 StandoutNature
Persistence of Mycobacterium tuberculosis in macrophages and mice requires the glyoxylate shunt enzyme isocitrate lyase
2000 StandoutNature
Dynamic Antigen-specific T-Cell Responses after Point-Source Exposure to Mycobacterium tuberculosis
2006
Moxifloxacin-containing Regimen Greatly Reduces Time to Culture Conversion in Murine Tuberculosis
2003
The population dynamics of antimicrobial chemotherapy
1997
Targeting Energy Metabolism in Mycobacterium tuberculosis , a New Paradigm in Antimycobacterial Drug Discovery
2017
Sulfatase-activated fluorophores for rapid discrimination of mycobacterial species and strains
2013 StandoutNobel
Sulfolipid Deficiency Does Not Affect the Virulence ofMycobacterium tuberculosisH37Rv in Mice and Guinea Pigs
2003
Drug Resistance in Tuberculosis
1990
23S rRNA base pair 2057–2611 determines ketolide susceptibility and fitness cost of the macrolide resistance mutation 2058A→G
2005 StandoutNobel
Dissection of Mycobacterium tuberculosis antigens using recombinant DNA.
1985
The pattern of resistance development to rifampicin in mycobacterium tuberculosis
1972
Characterization, sequence determination, and immunogenicity of a 64-kilodalton protein of Mycobacterium bovis BCG expressed in escherichia coli K-12
1987
Plasmid-influenced changes in Mycobacterium avium catalase activity
1989
Activation of macrophages in vivo and in vitro. Correlation between hydrogen peroxide release and killing of Trypanosoma cruzi.
1979
Antimicrobial agent resistance in mycobacteria: molecular genetic insights
1995
Effect of Mycobacterium tuberculosis-derived sulfolipid I on human phagocytic cells
1988
The membrane proteins of the vacuolar system I. Analysis of a novel method of intralysosomal iodination.
1980 StandoutNobel
Guidelines on the Diagnosis and Management of Pericardial Diseases Executive SummaryThe Task Force on the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology
2004 Standout
Evaluation of rapid radiometric method for drug susceptibility testing of Mycobacterium tuberculosis
1981
Visualization of mycobacterial membrane dynamics in live cells
2017 StandoutNobel
Interventions for treating tuberculous pericarditis
2017
Treatment of tuberculosis. The Mitchell lecture 1979.
1980
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
Bacterial Resistance to β-Lactam Antibiotics: Compelling Opportunism, Compelling Opportunity
2005 Standout
Outcome of chemotherapy in 107 patients with pulmonary tuberculosis resistant to isoniazid and rifampin.
1998
THE EPIDEMIOLOGY OF TUBERCULOSIS IN THE UNITED STATES
1997
Tuberculous Granulomas Are Hypoxic in Guinea Pigs, Rabbits, and Nonhuman Primates
2008
Optimizing ethambutol dosing among HIV/tuberculosis co-infected patients: a population pharmacokinetic modelling and simulation study
2019 StandoutNobel
Some observations on the genetics of isoniazid resistance in the tubercle bacilli.
1971
Zanvil Alexander Cohn 1926-1993.
1994 StandoutNobel
Machine Learning in Medicine
2019 Standout
A sulfated metabolite produced bystf3negatively regulates the virulence ofMycobacteriumtuberculosis
2006 StandoutNobel
Osmosensory signaling in Mycobacterium tuberculosis mediated by a eukaryotic-like Ser/Thr protein kinase
2013 StandoutNobel
Incidence of sarcoidosis in the Isle of Man.
1985
The Cutaneous Infiltrates of Leprosy
1982 StandoutNobel
THE MAGIC BULLETS AND TUBERCULOSIS DRUG TARGETS
2004
Molecular cloning and expression of a novel glycolipid sulfotransferase in Mycobacterium tuberculosis The GenBank/EMBL/DDBJ accession number for the sequence (gene Rv1373) reported in this paper is Z81011.
2002
Tuberculosis: Commentary on a Reemergent Killer
1992 StandoutScience
MmpL8 is required for sulfolipid-1 biosynthesis and Mycobacterium tuberculosis virulence
2003 StandoutNobel
In vitro activities of several new macrolide antibiotics against Mycobacterium avium complex
1989
An analysis of in vitro T cell responsiveness in lepromatous leprosy.
1985 StandoutNobel
Tuberculosis Epidemic Among Hospital Personnel
1989
Drug susceptibility testing of Mycobacterium tuberculosis: a neglected problem at the turn of the century.
1999
Subcellular Partitioning and Intramacrophage Selectivity of Antimicrobial Compounds against Mycobacterium tuberculosis
2017 StandoutNobel
Bactericidal action of ofloxacin, sulbactam-ampicillin, rifampin, and isoniazid on logarithmic- and stationary-phase cultures of Mycobacterium tuberculosis
1996
Double blind randomised placebo controlled trial of adjunctive prednisolone in the treatment of effusive tuberculous pericarditis in HIV seropositive patients
2000
In Situ Detection of Mycobacterium tuberculosis Transcripts in Human Lung Granulomas Reveals Differential Gene Expression in Necrotic Lesions
2002
MIC as a quantitative measurement of the susceptibility of Mycobacterium avium strains to seven antituberculosis drugs
1988
Genetic requirements for mycobacterial survival during infection
2003 Standout
The heat resistance of tubercle bacilli in the lungs of infected mice.
1961
Tuberculosis Epidemic among Hospital Personnel
1989
Monocyte responses to sulfatide from Mycobacterium tuberculosis: inhibition of priming for enhanced release of superoxide, associated with increased secretion of interleukin-1 and tumor necrosis factor alpha, and altered protein phosphorylation
1991
A single gene from yeast for both nuclear and cytoplasmic polyadenylate-binding proteins: Domain structure and expression
1986 StandoutNobel
Lipids of Putative Relevance to Virulence in Mycobacterium tuberculosis : Phthiocerol Dimycocerosate and the Attenuation Indicator Lipid
1974
The Stringent Response of Mycobacterium tuberculosis Is Required for Long-Term Survival
2000
Lipids of Putative Relevance to Virulence in Mycobacterium tuberculosis : Correlation of Virulence with Elaboration of Sulfatides and Strongly Acidic Lipids
1974
Restricted structural gene polymorphism in the Mycobacterium tuberculosis complex indicates evolutionarily recent global dissemination
1997 Standout
Sulfolipid I of Mycobacterium tuberculosis, strain H37Rv I. Purification and properties
1970
Unconventional screening approaches for antibiotic discovery
2015
A Fluorogenic Trehalose Probe for Tracking Phagocytosed Mycobacterium tuberculosis
2020 StandoutNobel
PapA1 and PapA2 are acyltransferases essential for the biosynthesis of theMycobacterium tuberculosisvirulence factor Sulfolipid-1
2007 StandoutNobel
Acute Modulation of Mycobacterial Cell Envelope Biogenesis by Front‐Line Tuberculosis Drugs
2018 StandoutNobel
Purulent pericarditis
2000
Synthesis and Structure−Activity Relationships of Aza- and Diazabiphenyl Analogues of the Antitubercular Drug (6S)-2-Nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824)
2010
A new evolutionary scenario for the Mycobacterium tuberculosis complex
2002 Standout
Discovery of sulfated metabolites in mycobacteria with a genetic and mass spectrometric approach
2002 StandoutNobel
Resazurin Microtiter Assay Plate: Simple and Inexpensive Method for Detection of Drug Resistance in Mycobacterium tuberculosis
2002 Standout
Mycobacterium aviumComplex Infection in the Acquired Immunodeficiency Syndrome
1991 Standout
Works of D.A. Mitchison being referenced
THE EMERGENCE OF ISONIAZID-RESISTANT CULTURES IN PATIENTS WITH PULMONARY TUBERCULOSIS DURING TREATMENT WITH ISONIAZID ALONE OR ISONIAZID PLUS PAS.
1964
The virulence in the guinea-pig of tubercle bacilli from patients with pulmonary tuberculosis in Hong Kong
1963
Protein synthesis is shutdown in dormantMycobacterium tuberculosisand is reversed by oxygen or heat shock
1998
Predictive In Vitro Models of the Sterilizing Activity of Anti-Tuberculosis Drugs
2004
Bactericidal activity of the diarylquinoline TMC207 against Mycobacterium tuberculosis outside and within cells
2010
Application of DNA fingerprinting with IS986 to sequential mycobacterial isolates obtained from pulmonary tuberculosis patients in Hong Kong before, during and after short-course chemotherapy
1993
The early bactericidal activity of rifabutin in patients with pulmonary tuberculosis measured by sputum viable counts: a new method of drug assessment
1993
Assessment of the Efficacy of New Anti-Tuberculosis Drugs
2008
CONTROLLED CLINICAL TRIAL OF COMPLETE OPEN SURGICAL DRAINAGE AND OF PREDNISOLONE IN TREATMENT OF TUBERCULOUS PERICARDIAL EFFUSION IN TRANSKEI
1988
High-dose rifampicin kills persisters, shortens treatment duration, and reduces relapse rate in vitro and in vivo
2015
Bactericidal and Sterilizing Activities of Antituberculosis Drugs during the First 14 Days
2003
The Diagnosis and Therapy of Tuberculosis During the Past 100 Years
2005
Tubercle Bacilli Resistant to Isoniazid
1954
ANTIGENIC DIVERSITY OF MYCOBACTERIUM TUBERCULOSIS AND MYCOBACTERIUM BOVIS DETECTED BY MEANS OF MONOCLONAL ANTIBODIES
1981
Mechanisms of Pyrazinamide Action and Resistance
2014
The curious characteristics of pyrazinamide: a review.
2003
Influence of pretreatment bacterial resistance to isoniazid, thiacetazone or pas on the response to chemotherapy of African patients with pulmonary tuberculosis
1963
A comparison of the virulence in Guinea-pigs of south indian and British tubercle bacilli
1960
Role of individual drugs in the chemotherapy of tuberculosis.
2000
Mechanisms of Tuberculosis Chemotherapy
1997
MYCOBACTERIA: LABORATORY METHODS FOR TESTING DRUG SENSITIVITY AND RESISTANCE.
1963
Preventive chemotherapy of tuberculosis in Cornell model mice with combinations of rifampin, isoniazid, and pyrazinamide
1996
Early Bactericidal Activity of Paromomycin (Aminosidine) in Patients with Smear-Positive Pulmonary Tuberculosis
2000
Virulence in the guinea-pig and sensitivity to pas and thiacetazone of tubercle bacilli from South Indian patients with pulmonary tuberculosis
1964
Modern methods for assessing the drugs used in the chemotherapy of mycobacterial disease
1996
How drug resistance emerges as a result of poor compliance during short course chemotherapy for tuberculosis.
1998
The Segregation of Streptomycin-Resistant Variants of Mycobacterium tuberculosis into Groups with Characteristic Levels of Resistance
1951
Virulence in the guinea‐pig, susceptibility to hydrogen peroxide, and catalase activity of isoniazid‐sensitive tubercle bacilli from South Indian and British patients
1963
Timing of relapse in short-course chemotherapy trials for tuberculosis.
2010
DRUG RESISTANCE IN MYCOBACTERIA
1984
Metronidazole has no antibacterial effect in Cornell model murine tuberculosis.
1998
Virulence in the guinea-pig and susceptibility to hydrogen peroxide of isoniazid-sensitive tubercle bacilli from South Indian patients
1964
Role of lipid content and hydrogen peroxide susceptibility in determining the guinea-pig virulence of Mycobacterium tuberculosis.
1982
Viable Counting of Mycobacterium tuberculosis in a Silica Gel Medium
1957
[The role of sensitivity tests in short-term chemotherapy].
1983
Modern methods for assessing the drugs used in the chemotherapy of mycobacterial disease
1996
Bactericidal Action of Gatifloxacin, Rifampin, and Isoniazid on Logarithmic- and Stationary-Phase Cultures of Mycobacterium tuberculosis
2005
The virulence in the guinea-pig of tubercle bacilli isolated before treatment from South Indian patients with pulmonary tuberculosis. I. Homogeneity of the investigation and a critique of the virulence test.
1961
Basic Mechanisms of Chemotherapy
1979
The therapy of pulmonary tuberculosis in Kenya: A comparison of the results achieved in controlled clinical trials with those achieved by the routine treatment services
1970
The sensitivity to thiacetazone and para-aminosalicylic acid and the virulence in the guinea pig of East African strains of mycobacterium tuberculosis
1969
Comparison of strains of mycobacterium tuberculosis from british, ugandan and asian immigrant patients: A study in bacteriophage typing, susceptibility to hydrogen peroxide and sensitivity to thiophen-2-carbonic acid hydrazide
1977
Response to treatment with isoniazid plus PAS of tuberculous patients with primary isoniazid resistance
1969
Tubercle bacilli resistant to isoniazid: virulence and response to treatment with isoniazid in guinea-pigs and mice.
1953
The prevalence of drug-resistant tubercle bacilli in untreated patients with pulmonary tuberculosis: A national survey, 1955–56
1957
The virulence in the guinea-pig of tubercle bacilli isolated before treatment from South Indian patients with pulmonary tuberculosis. 2. Comparison with virulence of tubercle bacilli from British patients.
1961
Bactericidal activity in vitro and in the guinea-pig of isoniazid, rifampicin and ethambutol
1976
Primary drug resistance in pulmonary tuberculosis in Great Britain: Second national survey, 1963
1966
Advances in techniques of testing mycobacterial drug sensitivity, and the use of sensitivity tests in tuberculosis control programmes.
1969
The Correlation of Bacteriophage Types of Mycobacterium tuberculosis with Guinea-pig Virulence and In vitro-indicators of Virulence
1978
Shortening the treatment of tuberculosis
2005
Detection of mRNA Transcripts and Active Transcription in Persistent Mycobacterium tuberculosis Induced by Exposure to Rifampin or Pyrazinamide
2000
Sterilizing Activities of Fluoroquinolones against Rifampin-Tolerant Populations of Mycobacterium tuberculosis
2003
The susceptibility to hydrogen peroxide of Indian and British isoniazid-sensitive and isoniazid-resistant tubercle bacilli
1960
Basic Mechanisms of Chemotherapy
1979
Regional variation in the guinea-pig virulence and other characteristics of tubercle bacilli
1970
Laboratory aspects of intermittent drug therapy
1971
The action of antituberculosis drugs in short-course chemotherapy
1985